A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, Combined With Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
Latest Information Update: 04 May 2022
At a glance
- Drugs Docetaxel (Primary) ; Elraglusib (Primary) ; Gemcitabine (Primary)
- Indications Ewing's sarcoma; Fibroma; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Osteosarcoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
Most Recent Events
- 30 Nov 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.(The study was stopped due to IND withdrawn )
- 17 Nov 2021 New trial record